Background:
Patients with musculoskeletal (MSK) disorders may remain on lengthy hospital outpatient waiting lists to be reviewed by a consultant doctor, although medical or surgical intervention may not be required (1,2). In 2012, a waiting list initiative saw the introduction of Advanced Practice Physiotherapists (APPs) across 16 hospitals in Ireland. APPs triage and manage patients awaiting a consultant doctor appointment, who are deemed non-urgent or unlikely to require surgery on screening of referral letters. APP scope of practice generally involves some traditionally medical-controlled acts such as: administering injections, ordering investigations/imaging, surgical listing and onward referral to hospital specialities; and depending on consultant doctor availability, their input may be sought on clinical decisions if required.
Objectives:
• Profile the national APP patient caseload • Establish the clinical outcomes of APP consultations Methods: A national database was established with all APPs (n=22) submitting patient data for 2014. These data were analysed using descriptive statistics. Background: DMARDs are beneficial for a number of rheumatic conditions. However, treatment effect may take a few weeks. On the other hand, patients may experience adverse effects (AEs) early on and they may not be able to follow complicated dosage titration regimen. In order to enhance treatment safety and empower self-management, rheumatic disease patients requiring initiation or change of DMARDs were recruited to a rheumatology nurse phone follow-up program. Objectives: (1) To evaluate the service outcomes of Rheumatology Nurse Phone follow-up Program and (2) explore the factors that may influence treatment adherence Methods: Upon initiation of DMARDs therapy at out-patient clinic or before hospital discharge, patients and/or their caregivers will be counseled for the new treatment plan and self-management knowledge by rheumatology nurse. A telephone follow-up by rheumatology nurse will be arranged within 4 weeks to monitor patients' condition. Treatment responses, AEs, drug concordance of patients and advice given in each phone consultation (PC) were recorded. Retrospective case review was performed. Results: There were 1230 episodes of PC performed by rheumatology nurse in 2015. 180 episodes of PC involved 76 patients (56 female) were randomly selected. The average number of PC was 2.4 times per case. The mean age of patient was 58 (24-85) years. Disease categories mainly involved rheumatoid arthritis (60.5%), systemic lupus erythematosus (7.9%), spondyloarthritis (5.3%) and gout (3.9%). The most common DMARDs prescribed were methotrexate (40.8%), hydroxychloroquine (27.6%), sulphasalazine (22.4%) and 39.5% of the study cases have received steroid courses. Among the 76 patients, 8 (10.5%) have taken wrong dosage and another 4 (5.3%) patients have not started therapy due to worries about potential AEs. Altogether 40 patients (52.6%) reported AEs after starting DMARDs. The most common AEs were rash, itchiness, dizziness, alopecia and oral ulcers. For non-adherence behaviour, 8 patients (10.5%) have self-stopped their medication and another 7 patients (9.2%) have self-adjusted the medication respectively. Eventually 90% of the cases were able to continue therapy with or without adjustment of regimes. Only 7 cases (9.2%) required interruption of current treatment or switching to other DMARDs due to AEs within the study period. The initiation of a pro-active telephone call at three months, to capture and act upon primary inefficacy and non-tolerance has been considered as a potential alternative method for waste reduction. Objectives: Establish the baseline level of biologic drug waste (via Homecare) following cessation of biologic treatment. Review whether a proactive phone call (and subsequent limitation of supply if appropriate) prior to the three month review at the start of biologic therapy can help reduce biologic waste. Establish whether there is scope to implement other initiatives to reduce waste in the department. Methods: Patients who had stopped or switched biologic treatments delivered through Homecare providers were identified using the trust's biologic database and clinic records. Information on biologic delivery quantities and schedule were provided by Homecare companies. Data was analysed used Microsoft Excel ® ; number (and cost in accordance with pharmacy tariffs) of doses "wasted" was calculated by referring the date of treatment cessation with the date and quantity of last biologics deliveries and patient stock levels as reported by the homecare company. Doses obtained free of charge were excluded. Baseline data was captured over a six month period. Four costs were calculated; (1) Total waste. (2) Wasted supply exceeding two months to assess whether an increase in delivery frequency to two monthly could reduce waste. (3) Waste from unopened deliveries to establish whether waste could be reduced by improved patient education around refusing deliveries in the event of treatment failure or intolerance. (4) Waste from the second biologic prescription issued as a result of stopping biologic at the three month review to assess viability of the proactive phone. A proactive patient phone call was then initiated and waste data captured for a three month period following this intervention. Results: 27 patients stopped treatment during the 6 months baseline data collection. 23 patients had drug waste totalling £ 32,140.80. The total value of wasted stock exceeding two months supply was £ 5,414.36. Three patients accepted deliveries for further supply and stopped treatment before opening final deliveries, creating a waste total of £ 5,509.09. Four patients stopped treatment at their three month review, £ 4,572.22 of additional biologic was supplied and then wasted as a result. Following the pro-active phone call intervention, 21 patients were contacted before their second supply was due and supply subsequently limited for 8 patients, four of whom stopped treatment at their next consultant review. Limiting supply in the four patients saved £ 6,682. Conclusions: Initiating a proactive phone call at three months following biologic initiation can reduce drug waste. Other initiatives such as patient education to refuse deliveries and increasing delivery frequency also appear viable waste reduction initiatives. Objectives: Since April 2015, the availability of Infliximab biosimilars offered a new potential for cost savings in limited financial resources of the healthcare system. In Austria, there is currently no open tendering for drugs dispensed at charge of sickness funds and biosimilars take a long time to gain an appreciable market share overall. A contract made between the public hospital operator and the regionale sickness fund of the Eastern Austrian county Burgenland (BGKK) offered a new opportunity regarding the interface problems due to the dually financed (inpatient and outpatient care is separately financed in Austria) health system. Only outpatient care is covered by regional sickness funds. Methods: With reference to the NOR-SWITCH study (1), confirming the interchangeability of the branded Infiximab and infliximab biosimilar, and the large price advantage of the latter, the BGKK agreed as an exception in the Austrian health system on direct reimbursement of infliximab to the public hospital operator (inpatient care). The cost savings were calculated based on the monthly invoices of the hospitals. Instead of 477.19 for 100 mg of branded infliximab, the price for biosimilar infliximab does not exceed 300.-. The 23 patients on biosimilar were infused with 9,400 mg infliximab overall. Results: After signing the agreement in December 2016, 23 consecutive patients, representing 82% of all patients on infliximab in Eastern Austrian county Burgenland, switched to or were incident users of an infliximab biosimilar, the 18% have not yet switched due to remaining stocks of branded infliximab or were adolescents where switching is not forced because of lacking data. According to the individual dosing and a price benefit of about 37%, monthly cost savings of about 16,650.00 could be generated. Conclusions: Despite availability of cost-effective infliximab biosimilars in Austria, the drugs did not gain significant market share, in contrast to the Scandinavian healthcare systems, <4% vs. >90% in the first half year of 2016. Further research is needed including clinical data to strengthen the results of this pilot study. Background: Teriparatide is licensed for upto two years to treat severe osteoporosis. It is the most expensive osteoporosis treatment available (around £ 3500 per year). Hence a locally adapted national NICE guidance is used for prescribing in our department, but the previous level adherence was uncertain. In 2011, a directory of services was agreed for our metabolic bone clinic. At the time a Rheumatology senior pharmacist review with the prescribing senior clinician was agreed on our teriparatide treatment pathway, including pre-treatment DXA, and a specified bone profile screen before treatment and for repeat prescribing at specified intervals. The agreement also incorporated access for our patients to senior pharmacist advice if needed via the department's secreterial team. Objectives: Our objective was to assess the impact of the senior pharmacist input on our adherence to the agreed guidelines in our Teriparatide pathway, including assessing treatment completion and response. Methods: Patients with osteoporosis who were started on Teriparatide between 2011-2015 were identified from pharmacy prescribing spreadsheets. A retrospective review of case notes of all patients were carried out. Data including age, gender, prior agents tried, pre-treatment bone profile, pre and post treatment DXA, and treatment completion were collected on a Microsoft Excel 2010 spreadsheet for processing and descriptive statistics. Results: 33 patients who were started on teriparatide treatment between 2011-2015 were identified (29 female and 4 male). Mean age was 76.2 (range 63-92). All had pre-treatment DXA, and 32 (97%) were compliant with recommendations for initiation of teriparatide treatment with respect to DXA (one patient borderline). All 33 patients had a pre-treatment bone profile within acceptable limits before start of treatment (adjusted Calcium, Serum Parathyroid Hormone, Vitamin D level, e-gfr). 28 (84.8%) patients tried one agent before initiation of Teriparatide treatment and 5 (15.2%) patients tried 2 agents. 24 (72.7%) patients completed the full course of recommended treatment. 11 out of 24 patients who completed Teriparatide treatment have had post-treatment DXA. 3 out of 24 patients who completed Teriparatide treatment had a fragility fracture after treatment. Conclusions: This audit confirms the benefit of incorporating Rheumatology senior pharmacist review in the pathway from the excellent compliance with guidelines in initiating and managing Teriparatide noted in the results. This is likely to have also contributed to the high completion rate of the treatment course. However, only 11 out of 24 had post treatment DXA, and this needs improvement by the next audit cycle, through input of senior clinicians who are in charge of requesting DXA. We would, therefore, recommend incorporating senior pharmacist input for review in teriparatide treatment pathways routinely. 
